|
|
||||||||


* Department of Integrative Physiology, University of North Texas Health Science Center, Fort Worth, Texas 76107; and
Clinical Research Laboratory of Hypoxia Medical Academy, Moscow 123367, Russia
1 To whom requests for reprints should be addressed at Department of Integrative Physiology, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, TX 76107-2699. E-mail: pzong{at}hsc.unt.edu
| Abstract |
|---|
|
|
|---|
Key Words: cardiac protection intermittent hypoxia myocardial infarction collateral blood flow
| Introduction |
|---|
|
|
|---|
There is increasing interest in intermittent hypoxia training (IHT) to improve exercise performance, enhance acclimatization to high altitude, and prevent and treat various illnesses (1418). This training involves multiple cycles of brief (~5 mins), moderate hypoxia interspersed with normoxia, often on a daily basis for several weeks. Because neither sojourns to high altitude nor hypobaric chambers are required for normobaric IHT, it can readily be implemented in the clinic. Considering the demonstrated cardioprotective effects of hypoxia in rodents, it seemed conceivable that a clinically relevant IHT protocol would be cardioprotective in dogs. Thus, the current investigation was designed to test this hypothesis. We found that IHT was remarkably effective in protecting canine hearts from infarction and arrhythmias due to coronary artery occlusion and reperfusion.
| Materials and Methods |
|---|
|
|
|---|
Intermittent Hypoxia Training Protocol.
Dogs were exposed to intermittent, normobaric hypoxia according to the protocol described in Table 1
. Dogs were subjected to one session per day for 20 consecutive days. For this training, the dogs were placed in a Plexiglas chamber (interior dimensions: 114 x 33 x 71 cm), and N2 was introduced into the chamber to reduce fraction of inspired oxygen (FIO2) to the prescribed level (Table 1
). Chamber O2 was monitored with an Alpha Omega Instruments, Series 2000 O2 analyzer (Cumberland, RI). The dogs showed no distress during hypoxic training. For sham IHT, the 20-day IHT protocol was followed, except instead of N2, compressed air was introduced into the chamber to keep the FIO2 at 20%.
|
The dogs were fasted overnight and then anesthetized with sodium pentobarbital (30 mg/kg, iv). The dogs were intubated and mechanically ventilated with room air containing supplemental O2. Arterial blood samples were collected at frequent intervals and analyzed for PO2, PCO2, and pH, which were kept within normal physiological limits by adjusting supplemental O2, tidal volume, and respiratory rate. Supplemental pentobarbital was administered as needed to maintain stable anesthesia through a vinyl catheter positioned in a femoral vein. A saline-filled vinyl catheter was inserted into the thoracic aorta via a femoral artery to measure aortic pressure. In the other femoral artery, two Tygon catheters were placed to collect reference blood samples required for measuring coronary collateral flow with the radioactive microsphere technique (19). The heart was exposed through a left thoracotomy in the fifth intercostal space and suspended in a pericardial cradle. The left anterior descending (LAD) coronary artery was isolated near its origin, and a silk snare was passed around it. A Millar catheter-tip pressure transducer (Millar Instruments, Houston, TX) was inserted through the left atrium and advanced to the left ventricle to measure left ventricular pressure and dP/dt. Another vinyl catheter was positioned in the left atrium for injecting microspheres. Limb lead II of the electrocardiogram was recorded along with pressures and dP/dt on a Grass polygraph (Grass Medical Instruments, Quincy, MA). Body temperature was monitored with a hypodermic needle probe and maintained at 36.5°37.5°C with a circulating H2O heating pad.
When surgical preparations were complete and the animal stable, the LAD was occluded for 1 hr by tightening the snare and then allowed to reperfuse for 5 hrs after releasing the snare. Lidocaine (1.0 mg/kg, iv) was administered 1 min before LAD occlusion and 1 min before LAD reperfusion.
Hemodynamic and cardiac function variables were measured before and at the midpoint of the LAD occlusion coincident with microsphere injection, at 60 mins of LAD occlusion, and at 1, 3, and 5 hrs of LAD reperfusion. At 5 hrs of reperfusion, heparin (500 U/kg, iv) was administered to facilitate coronary artery perfusion to demarcate the LAD perfusion territory at risk of infarction (see below).
Coronary Collateral Blood Flow Measurement.
Because the extent of myocardial infarction is highly dependent on the amount of collateral flow, which varies among dogs, radioactive microspheres were injected at the midpoint of the LAD occlusion period to measure coronary collateral blood flow into the LAD region and in the normally perfused left circumflex region (19). The microspheres were agitated on a vortex mixer and in an ultrasonic bath for at least 15 mins before use. Microspheres (5 million; 15-µm diameter) labeled with 46Sc, 85Sr, or 141Ce were injected into the left atrium followed by a gentle 10-ml saline flush. Beginning just before and continuing for 3 mins after microsphere injection, duplicate reference arterial blood samples were withdrawn from the thoracic aorta at a constant rate of 3 ml/min. Adequacy of microsphere mixing in the blood perfusate was verified by comparing radioactivities in the duplicate reference blood samples.
After slicing the ventricle and determining the area at risk (AAR) of infarction and the infarct size (see below), ventricular samples were cut from the central ischemic region and from the left circumflex region. Lateral border zones were excluded to avoid errors associated with measuring blood flow in samples of heterogeneous composition. The tissue samples were divided into endocardial, mid-myocardial, and epicardial thirds (~1 g each). Radioactivities of tissue and blood reference samples were measured in a Packard gamma counter (Packard Instrument Company, Meriden, CT). Blood flow in these tissue samples (ml·min1·g1) was calculated as previously described (19, 20).
Collateral flow in the AAR was evaluated in two ways. An average collateral flow was computed by averaging the endocardial and mid-myocardial flows of all samples of the AAR of each heart. This average collateral flow in the central region of the AAR has previously been used to evaluate cardioprotective interventions (2124). A minimum collateral flow was also computed by averaging the endocardial and mid-myocardial flows in the slice of the AAR with the lowest collateral flow.
Determination of Myocardial Infarct Size (IS).
The size of the AAR was determined with a dual-perfusion technique applied in situ (21, 25). The descending aorta and the brachiocephalic artery were ligated, and a large-bore cannula was advanced into the root of the aorta through the left subclavian artery. The LAD was cannulated at the site of occlusion. Small-bore catheters within the aortic and LAD cannulas were connected to pressure transducers, so aortic root and LAD pressures could be monitored during the dual-perfusion procedure. The aortic and LAD cannulas were connected to pressurized reservoirs containing 2.5% Evans blue dye and normal saline, respectively. The left and right ventricles were vented to atmospheric pressure by cannulas inserted through the apex of the heart. When these preparations were complete, the left and right coronary arteries were perfused from the aorta with saline containing Evans blue dye, whereas the LAD was perfused with saline alone. These solutions were infused simultaneously for 12 min at constant pressures of 85 mm Hg. This procedure delineated the ischemic area of the LAD perfusion territory at risk of infarction, as blue dye was excluded from this region. The heart was excised for measurements of infarct size and regional myocardial blood flow.
After excision of the atria and right ventricle, the left ventricle (LV) was frozen and stored overnight before being cut into four to six transverse slices approximately 1-cm thick. The weight of the ventricular slices was measured (LV), and then these slices were incubated in triphenyl tetrazolium chloride (1% w/v) in phosphate buffer (0.1 mol/l, pH 7.4) at 37°C for 20 mins, which imparts a deep red color to non-infarcted tissue (26). Undyed, infarcted tissue was resected and weighed, and then the remaining red tissue was cut away from the adjacent blue tissue and weighed. The weight of the red tissue plus the weight of the infarcted tissue equaled the AAR. IS/AAR and AAR/LV were computed.
Statistical Analyses.
Values are expressed as mean ± SE. Hemodynamic data were analyzed with a two-way, repeated measures analysis of variance (ANOVA) to detect effects of (i) treatment (i.e, IHT, sham training, no training) and (ii) time period during the acute experimental protocol (i.e., baseline, 30 mins ischemia, 60 mins ischemia, 1 hr reperfusion, 3 hrs reperfusion, and 5 hrs reperfusion). Infarct size/area at risk of infarction, AAR/LV, regional coronary blood flow, and arterial hemoglobin and O2 content were analyzed with completely randomized ANOVA to detect differences between IHT, sham training, and no training. When significance (P < 0.05) was detected by ANOVA, a Student-Newman-Keuls multiple comparison test was performed. Statistical procedures were performed with GB-Stat statistical software, version 9.0 (Dynamic Microsystems, Silver Spring, MD).
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Many investigations of interventions to protect ischemic myocardium have been stimulated by the observation in 1986 by Murry et al. that a brief period of acute ischemia reduced the extent of myocardial infarction resulting from subsequent, more prolonged ischemia (24, 27). In fact, the cardioprotective effect of hypobaric hypoxia had been reported many years earlier (3, 4, 28). Potentially beneficial effects of hypoxia for cardiac protection have received much less attention compared to ischemic preconditioning. This seems somewhat surprising because hypoxic exposure occurs normally at high altitude and can readily be accomplished in the laboratory or clinic. However, recently a hypobaric IHT protocol was employed to treat 46 patients with coronary heart disease and dyslipidemia; 37 patients were followed for 10 months, and none developed myocardial infarction (18).
To date, experimental investigations of cardioprotective effects of simulated high altitude or intermittent normobaric hypoxia have been performed only in small animals (mice, rats, guinea pigs). Neckar et al. subjected rats to intermittent hypobaric exposures simulating 50007000 m altitude for 8 hrs/day, 5 days a week. After 2432 exposures, the rats were anesthetized and subjected to 2030 mins LAD occlusion followed by 4 hrs reperfusion. They found that adaptation of rats to intermittent hypobaric hypoxia decreased IS/AAR by 15%25% (9, 10). It should be noted that in the current study, 20 days of intermittent normobaric hypoxic training produced more substantial protection against myocardial infarction in dogs than the protection observed in rodents adapted to more severe intermittent hypobaric hypoxia. Furthermore, the current study also indicates that IHT is effective in protecting canine myocardium from infarction when the duration of coronary artery occlusion has been extended to 60 mins compared with the 2030 mins regional myocardial ischemia produced by Neckar et al. in rats (9, 10). However, it must be acknowledged that dogs have greater native coronary collateral flow than rats, and this factor could have contributed to the smaller infarcts observed in the current study.
Xi et al. found that 4 hrs acute normobaric systemic hypoxia (FIO2 = 10%) protected isolated mice hearts from infarction when the hearts were subjected to ischemia/reperfusion 24 hrs after treatment (12). Similar findings were reported by Cai et al., who found this cardioprotection present at 24 hrs but not at 30 mins after hypoxia (13). We did not test the resistance of myocardium to ischemia immediately after IHT, but our results are consistent with the myocardial protection observed by others 1 day after IHT (9, 10, 12, 13). The results of Cai et al. (13) suggest that the protective mechanism activated by IHT may differ from that activated by ischemic preconditioning, because ischemic preconditioning can induce both early and delayed phases of resistance to ischemic injury (24, 27, 29, 30). The minimum duration of IHT required to produce significant protection against myocardial infarction and the duration of this protection in the canine model of ischemia/reperfusion remains to be determined.
It has been noted that adaptation to hypobaric hypoxia protects the rat heart against ischemic ventricular tachyarrhythmias (5, 7, 8, 10). Meerson et al. reported that the duration of extrasystole and VF induced by acute coronary ligation in conscious rats adapted to hypobaric hypoxia was decreased 2- to 3-fold compared to that of control rats (5). In open-chest rats exposed to intermittent hypobaric hypoxia, Neckar et al. observed no VF, compared with the 9.1% incidence of VF in normoxic control rats (10). In the current study, VF did not occur in any of the 6 IHT dogs subjected to 60 mins LAD occlusion and 5 hrs reperfusion. In contrast, two of six sham-trained dogs and three of five untrained dogs developed VF during the same acute experimental protocol. The apparent antiarrhythmic effect of IHT cannot be attributed to the cardioprotective effect of lidocaine (31), because the same dose of lidocaine was used in all animals during the acute experiment.
Acute hypoxia-induced myocardial protection of the canine heart has been reported by Shizukuda et al., who perfused the LAD of anesthetized dogs with severely hypoxic blood (<1 ml O2/100 ml blood) for 5 mins in a protocol to mimic ischemic preconditioning. After 10 mins of normoxic perfusion, the LAD was then occluded for 1 hr and reperfused for 5 hrs, as in the current study. Infarct size in these hypoxic preconditioned hearts was 7.2% of the AAR compared to 22.4% in untreated control hearts (21). In the current study, 20 days of IHT was more cardioprotective than acute hypoxic preconditioning. Furthermore, Shizukuda et al. found that acute hypoxic preconditioning provided no protection against VF (21). Therefore, the protective mechanism activated acutely by hypoxic preconditioning may differ from that activated by more prolonged IHT.
As with ischemic preconditioning, there is currently no definitive mechanism to explain intermittent hypoxia-induced cardioprotection. Kolar reviewed putative mechanisms of hypoxic adaptation of myocardium (32). These mechanisms include altered (i) myocardial vascularity and coronary blood flow, including collateral flow, (ii) blood hematocrit and hemoglobin content, (iii) myocardial myoglobin concentration, (iv) energy metabolism, (v) neurohumoral factors, (vi) antioxidant enzymes, (vii) stress proteins, (viii) prostaglandins, and (ix) adenosine release. Recently, Asemu et al. (7), Neckar et al. (9), and Zhu et al. (11) reported evidence that ATP-dependent potassium channels are involved in hypoxia-mediated cardioprotection. Xi et al. demonstrated that the infarct-limiting effect of acute systemic hypoxia is triggered and mediated by inducible nitric oxide synthase but not by endothelial nitric oxide synthase or cyclooxygenase-2 (12). Cai et al. found that erythropoietin protected rodent hearts in a manner similar to intermittent hypoxia, and that this protection was critically dependent on activation of hypoxia-inducible factor 1 (13). Thus, redundant mechanisms may be involved in the cardioprotection conferred by IHT, and more research is required to further clarify the contributions of these and possibly other mechanisms.
Data from this study do permit comment on two potential protective mechanisms. First, the hemoglobin and arterial O2 contents of IHT dogs were not different from those of sham-trained and untrained dogs, so the amount of O2 transported in blood flowing through collateral vessels was not enhanced by IHT. These results do not exclude a role for erythropoietin but suggest that its effect would have been independent of its stimulation of red blood cell production. Second, augmented coronary collateral flow is not required for IHT-induced cardioprotection, as essentially no infarction occurred in four IHT dogs that had very low collateral flow (Fig. 1
). However, we did not measure collateral flow prior to IHT, so we cannot exclude an effect of IHT on collateral vessel development.
In summary, 20 consecutive days of IHT provided remarkable protection against myocardial infarction and ventricular tachyarrhythmias in a canine model of 60 mins coronary artery occlusion and 5 hrs reperfusion. This cardioprotection did not result from increased arterial O2 carrying capacity or increased coronary collateral blood flow.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received for publication December 22, 2003. Accepted for publication May 21, 2004.
| References |
|---|
|
|
|---|
-Adrenergic vasoconstrictor tone limits right coronary blood flow in exercising dogs. Exp Biol Med 229:312322, 2004.This article has been cited by other articles:
![]() |
M. E. Jung, J. W. Simpkins, A. M. Wilson, H. F. Downey, and R. T. Mallet Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats J Appl Physiol, August 1, 2008; 105(2): 510 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-G. Ryou, J. Sun, K. N. Oguayo, E. B. Manukhina, H. F. Downey, and R. T. Mallet Hypoxic Conditioning Suppresses Nitric Oxide Production upon Myocardial Reperfusion Experimental Biology and Medicine, June 1, 2008; 233(6): 766 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hlavackova, J. Neckar, J. Jezkova, P. Balkova, B. Stankova, O. Novakova, F. Kolar, and F. Novak Dietary Polyunsaturated Fatty Acids Alter Myocardial Protein Kinase C Expression and Affect Cardioprotection Induced by Chronic Hypoxia Experimental Biology and Medicine, June 1, 2007; 232(6): 823 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Manukhina, H. F. Downey, and R. T. Mallet Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia. Experimental Biology and Medicine, April 1, 2006; 231(4): 343 - 365. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |